MSD

News

BioNTech buys Biotheus and its Keytruda rival for $950m

BioNTech is clearly impressed with what it has seen with partner Biotheus' bispecific antibody for cancer, opting to buy the company outright to get full control of the drug.

News

vaccine vial held by hands in surgical green gloves

MSD, Moderna start phase 3 adjuvant lung cancer trial

MSD and Moderna have kicked off another phase 3 trial of their personalised cancer vaccine V940 used alongside MSD's PD-1 inhibitor Keytruda, this time focusing on patients with earlier-sta

News

MSD buys Modifi for $1.3bn to boost oncology pipeline

MSD has acquired Yale University spinout Modifi Biosciences, claiming ownership of a potential new class of therapeutics for difficult-to-treat brain tumours, including glioblastomas.

News

Gilead, MSD say HIV combo could be weekly, oral HIV drug

In a phase 2 trial, an antiretroviral combination developed by Gilead Sciences and MSD suppressed HIV with a single weekly oral dose, raising the hope of a new treatment option for patients

News

MSD preparing to take on Beyfortus with RSV antibody

New phase 2b/3 trial results with MSD's experimental respiratory syncytial virus (RSV) antibody clesrovimab have fired a shot across the bows of AstraZeneca and Sanofi, currently predicting

News

NICE backs first targeted therapy for ALK+ lung cancer

Roche's Alecensa has been recommended for routine NHS use as an adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first targeted therapy for this indication.

BioNTech buys Biotheus and its Keytruda rival for $950m

MSD, Moderna start phase 3 adjuvant lung cancer trial

MSD buys Modifi for $1.3bn to boost oncology pipeline

Gilead, MSD say HIV combo could be weekly, oral HIV drug

MSD preparing to take on Beyfortus with RSV antibody

NICE backs first targeted therapy for ALK+ lung cancer

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

MSD

Editor's Picks